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c University of Pécs, Doctoral School of Chemistry, Department of Chemistry, Faculty of Sciences, Pécs, Hungary 
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Dendritic cells (DCs), as potent phagocytes engulf dead cells and present peptide fragments of tumor antigens or 
pathogens derived from infected cells to naïve CD8+ T-lymphocytes. Dendritic cells can also induce apoptosis in 
target cells, thus getting an opportunity to sample their microenvironment. Here, we present that the superna-
tants of LPS- or CL075-activated DCs induced cell death in different cell lines, but during the differentiation to 
mature DCs, they lost their cytotoxic potential. Dexamethasone-pre-treated tolerogenic DCs induced less inten-
sive death indicating that the tissue microenvironment can downregulate DC-mediated killing. Exploring the 
signaling of DC-induced cell death, we observed that the supernatant of activated DCs induced TNF-dependent 
cell death, since TNF antagonist blocked the cytotoxic activity of DCs, contrary to inhibitors of Fas and TRAIL 
receptors. We identified that the DC-induced killing is at least partially a RIPK1-dependent process, as RIPK1 
positive target cells were more susceptible to DC-induced cell death than their RIPK1 deficient counterparts. 
Moreover, both the elevated phosphorylation of RIPK1 and the increase in RIPK1-caspase-8 interaction in target 
cells suggest that RIPK1-mediated signals contribute to DC supernatant-induced cell death. We also proved that 
the cytotoxic activity of DC-derived supernatant induced apoptosis in the target cells and not necroptosis, as it 
was completely abrogated with the pan caspase inhibitor (Z-VAD), while the necroptosis inhibitor (Nec-1) had no 
effect. 
Our work revealed that the supernatant of activated DCs induces the apoptosis of target cells in a RIPK1- 
dependent manner. This phenomenon could be relevant for the initiation of cross-presentation and may 
broaden the plethora of cytotoxic mechanisms acting against tumor cells.   
1. Introduction 
Dendritic cells (DCs) work as sentinels of the immune system and 
provide connection between innate and adaptive immunity. Immature 
DCs (iDCs) detect and phagocyte incoming pathogens in peripheral tis-
sues. Upon activation, iDCs leave the site of infection and migrate into 
lymph nodes, during which time they fully differentiate into mature DCs 
(mDC), and where they present antigens derived from the phagocyted 
pathogen to naïve T cells (Clatworthy et al., 2014). DCs are also able to 
engulf dead cells and present antigenic peptides both on MHCII and 
MHCI molecules. The latter, so called cross-priming process initiates 
cytotoxic T cell responses against viruses that do not infect DCs and 
tumors that originate from non-DCs (Bousso, 2008). In recent years, 
various regulated cell death pathways have been described and char-
acterized with different immunological outcomes including receptor- 
interacting protein kinase 1 (RIPK1)-mediated apoptosis and nec-
roptosis (Wang et al., 2008). These special, RIPK1-dependent routes of 
cell death have been published to increase the cross-presentation and 
the immunogenicity of DCs and in addition to playing a physiological 
role in enhancing innate immunity, regulate T lymphocyte activation 
(Yatim et al., 2015). 
Thus, cell death is inevitably the very first step in the induction of a 
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cytotoxic T cell response. Cell death providing cellular debris for cross- 
priming can occur as a result of a passive, intrinsic process via a pro-
grammed apoptotic pathway or due to active mechanisms via the 
cytotoxic effect of the pathogens or induced by the immune system itself. 
In addition to their efficient antigen-presenting function, the 
contribution of DCs to the generation of various cell death signals has 
also been widely demonstrated (Vidalain et al., 2001; Chan and Hous-
seau, 2008; Chauvin and Josien, 2008). However, the physiological role 
of DC-induced killing is still not clearly understood. The direct cytotoxic 
capacity of DCs is mainly related to their immature phenotype localized 
in tissues (Janjic et al., 2002), but an effective pathogen clearance by 
iDCs is unlikely, as activated dendritic cells leave the site of infection 
(Chan and Housseau, 2008). The exact molecular background underly-
ing the cytotoxicity of DCs is still yet to be defined, as it can be related to 
either a direct cell–cell contact-mediated action or soluble cytotoxic 
mediators released by DCs (Lakomy et al., 2011). The contribution of the 
known death ligands, such as TNF (Vidalain et al., 2001; Joo et al., 2002; 
Lu et al., 2002), TRAIL (Vidalain et al., 2001, 2000; Lu et al., 2002), Fas 
(Burdelya et al., 2013; Salamone et al., 2010); lymphotoxin α and β (Lu 
et al., 2002) in DC-induced killing mechanisms has already been 
demonstrated. 
DC-mediated cross-presentation can be either up- or down-regulated 
by the immunological microenvironment (Anderson et al., 2008); 
however, it is not known how the immunological conditions modify the 
cytotoxic potential of DCs. Infected cells produced type I interferons as 
alarm signals for DCs. Indeed, DCs express high levels of MHC and co- 
stimulatory molecules in the presence of Interferon-α (IFN- α), there-
fore they stimulate naïve CD4+ T cells (Carbonneil et al., (Jul 2004).); 
and naïve CD8+ T cells via cross-presentation (Schiavoni et al., 2013). 
Glucocorticoids (GCs) induce immune suppression by modulating DC 
differentiation, maturation, and function in the very first steps of the 
immune responses (Hunzeker et al., 2011). GCs may also suppress CD8+
T cell-mediated immunity, at least in part because they reduce the cross- 
presenting ability of DCs (Im et al., 2014). 
We suppose that DC-induced killing is rather a mechanism to sample 
the surrounding microenvironment for intracellular pathogen- or tumor- 
derived antigens, by allowing the iDC to phagocytose and cross-present 
dead cell-derived antigens. Here, we provide evidence that supernatants 
of short-term activated moDCs induce TNF-dependent apoptosis of 
Jurkat cells in a RIPK1-dependent manner. We also demonstrate that 
GC-induced tolerogenic conditions decrease the cytotoxic capacity of 
DCs. 
2. Materials and methods 
2.1. Antibodies and reagents 
Antibodies and reagents used were: Z-VAD (ApexBio), TNFR1:Fc 
(Adipogen), Trail:Fc (ProSpec Protein Specialist), Fas:Fc (R&D System), 
TNF-α, IL-10 and TGFß (PeproTech), propidium iodide /PI/ (Sigma- 
Aldrich), a SMAC mimetic /Birinapant/ (LC Laboratories), necrostatin-1 
(Abcam), Anti-RIPK1 (BD Biosciences), anti-pRIPK1 (Cell Signaling), 
anti-Caspase-8 (Cell Signaling) and anti-β-actin (Sigma-Aldrich), anti- 
rabbit and anti-mouse antibodies conjugated to horseradish peroxi-
dase (GE Healthcare). 
2.2. Generation of monocyte-derived DCs 
Monocyte-derived DCs (moDC) were separated as it was published 
(Bene et al., 2017). Briefly, monocytes were purified by anti-CD14 
microbeads from PBMCs and were cultured in the presence of 100 ng/ 
ml IL-4 (PeproTech) and 80 ng/ml GM-CSF (Gentaur Molecular Prod-
ucts) for 5 days. 
2.3. Generation of monocyte-derived IFN DCs 
IFN-moDCs were generated by culturing isolated monocytes in the 
presence of 1000 U/ml rhIFN-a (Roferon-A) and 40 ng/ ml GM-CSF and 
for 5 days. 
2.4. Generation of monocyte-derived dexamethasone DCs 
Dexamethasone DCs (dexa DCs) were generated by culturing isolated 
monocytes with 20 ng/ml IL-4, 0.25 µM dexamethasone (Sigma-Aldrich) 
and 100 ng/ml GM-CSF for 5 days. 
2.5. Collection of DCs (moDC, IFN DC, dexamethasone DC) supernatants 
DCs (moDC, IFN DC, dexa DC) were stimulated on day 5 of the dif-
ferentiation with Toll-like receptor ligands CL075 (1 µg/ml, Sigma) and 
LPS (0.5 µg/ml, InvivoGen) for 30 min. After 3 washing steps 4.0 × 106 
cells/ml DCs were incubated in fresh serum-free RPMI 1640 medium 
(Sigma-Aldrich) for 2, 8 or 24 h and the supernatants of DCs were 
harvested. 
2.6. Generation of monocyte-derived mDCs 
To generate LPS preconditioned DCs, moDCs were treated on the 
fifth day of differentiation for 24 h with 100 ng/ml LPS. To collect the 
supernatant, 24 h LPS pre-conditioned DC was reactivated with TLR- 
ligands for 30 min and after washing steps the supernatants were har-
vested for 2 h, in the same way as in the case of short term activated DCs. 
2.7. Cell lines 
SVT35 Jurkat and HT-29 cell lines were cultured in RPMI 1640 
medium (Biosera). The media was supplemented with 10% FCS (Gibco), 
2 mM L-glutamine (Biosera) and 40 mg/l Gentamicin (Sigma-Aldrich). 
HUVECs (Sigma-Aldrich) were cultured in M199 (Gibco) media sup-
plemented with 20% FCS (Gibco), 2 mM L-glutamine (Biosera), 1% 
penicillin/streptomycin (Gibco) and with EGMTM-2 Endothelial Single-
Quots™ Kit (Lonza) following the manufacturer’s instructions. These 
cell lines were maintained at 37 ◦C in a humidified atmosphere con-
taining 5% CO2. 
2.8. Measurement of cytokine concentration 
Supernatants of moDCs were harvested 2 h after activation, and the 
concentrations of TNF-α, IL-6 and IL-10 cytokines were measured using 
OptEIA kits (BD Biosciences) following the manufacturer’s instructions. 
2.9. Membrane integrity 
Total cell death was examined based on propidium iodide (PI) uptake 
by BD FACS Calibur flow cytometer (BD Biosciences). Data were 
analyzed using FlowJo software (Tree Star). 
2.10. SubG1 measurement 
DNA fragmentation was detected based on subG1 peak. Following 
fixation in ice-cold 70% ethanol, cells were washed in a 38 mM citrate 
buffer (pH 7.4) and incubated for 15 min with 50 µg/ml PI. The subG1 
population was determined using flow cytometer. Representative fig-
ures of this method are shown in Supplementary Fig. 1. 
2.11. Caspase 3/7 assay 
SVT35 Jurkat cells were incubated in the presence of the supernatant 
of activated DCs or 20 ng/ml TNF-α for 24 h at 37 ◦C. In 24 h, the 
caspase-3/7 activity was measured using an Apo-ONE Homogeneous 
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Caspase-3/7 assay kit (Promega) following the manufacturer’s 
instructions. 
2.12. Immunoprecipitation 
SVT35 Jurkat cells were incubated in the presence of the supernatant 
derived from 2 h activated DCs or the combination of TNF-α and SMAC 
mimetic for 1 h at 37 ◦C, then resuspended in a lysis buffer with 1% 
Triton-X 100 (Sigma-Aldrich) in the presence of protease inhibitor 
cocktail (Sigma-Aldrich) and incubated for 30 min at 4 ◦C. The lysate 
was recovered by centrifugation for 10 min at 13.000 rpm at 4 ◦C and 
mixed with Protein G beads (GE Healthcare) pre-coated with the anti- 
caspase-8 (Cell Signaling) antibody. The content was gently rotated at 
4 ◦C overnight. Next day, the beads were washed, 2X Laemmli sample 
buffer was added to them, were subjected to boiling for 5 min at 95 ◦C, 
and then samples were recovered by centrifugation for 10 min at 13.000 
rpm. Protein extractions were fractionated by SDS-PAGE. The RIPK1- 
Caspase-8 interaction was visualized by western blot using anti-RIPK1 
antibody (BD Biosciences). Immunoprecipitation with anti-RIPK1 was 
performed the same way and the intensity of Caspase-8 binding was 
examined by western blot. 
2.13. Western blotting 
Western blot analysis of proteins was performed according to 
standard protocols (Varga et al., 2020). Briefly, cells were lysed in 2X 
Laemmli sample buffer and were fractionated by SDS-PAGE and trans-
ferred onto nitrocellulose membranes (Bio-Rad Laboratories). Mem-
branes were developed with the indicated antibodies using the 
SuperSignal ECL system (Thermo Fischer Scientific). 
2.14. Statistical analysis 
Two-way ANOVA or one-way ANOVA was used for multiple com-
parisons followed by Sidak’s multiple test. Mean of ± SD are depicted. 
GraphPad Prism software was used for data analyses. Significance was 
indicated as *P < 0.05; **P < 0.01; ***P < 0.005; and ****P < 0.0001. 
3. Results 
3.1. The supernatant of dendritic cells induces cell death 
To demonstrate the ability of DCs to induce cell death, moDCs were 
activated with ligands of intracellular and cell surface PRRs, namely 
with CL075 or LPS for 30 min. Following activation, ligands were 
washed out completely and the cells were incubated for an additional 2 
h in fresh serum-free medium. SVT35 Jurkat cells were then activated 
with the collected supernatants (DCsup) of these short term activated 
DCs for 24 h. While the supernatants of untreated DCs exhibited minimal 
cytotoxic activity, supernatants collected after activation with either 
Fig. 1. The supernatant of immature dendritic cells 
induces cell death. (A-B) SVT35 Jurkat, (C) HT-29 
cells or (D) HUVECs were treated with the superna-
tants of unstimulated, CL075-(1 μg/ml) or LPS-(0.5 
μg/ml) activated dendritic cells. After 24 h, the extent 
of cell death was determined by measuring the subG1 
peak or (B) the caspase 3/7 activation was determined 
by measuring the luminescence intensity. (E) Jurkat 
cells were triggered with the supernatants of unsti-
mulated, CL075-(1 μg/ml) or LPS- (0.5 μg/ml) acti-
vated DC and the supernatant of LPS preconditioned 
DCs. After 24 h, cell death was determined by 
measuring the subG1 peak. The figures show the 
average of five independent experiments.   
Z. Varga et al.                                                                                                                                                                                                                                   
Immunobiology 226 (2021) 152032
4
CL075 or LPS induced intense cell death of SVT35 Jurkat cells as we 
detected by subG1 peak or caspase 3/7 activity (Fig. 1A-B). DCsup- 
mediated cytotoxicity was not limited to the Jurkat cells, as DCsup 
also induced significant cell death in the HT-29 cell line and HUVECs 
(Fig. 1C-D). However, the DCs themselves were resistant to the cytotoxic 
effect induced by DCsup (Supplementary Fig. 2). Next, we compared the 
effects of supernatants of short term activated DC and LPS precondi-
tioned DCs. The supernatant of LPS preconditioned induced less efficient 
killing of Jurkat cells than that of short term activated DCs. These results 
indicate that DCs acquire cytotoxic ability after PRR-induced short term 
activation (Fig. 1E). 
3.2. Supernatant of short term activated DCs induces cell death in a TNF- 
dependent manner 
It has been published that DC-induced cell death is induced by death 
receptor (DR) activation, but the results as to how DR achieves this effect 
are contradictory (Chan and Housseau, 2008). Because Jurkat cells are 
sensitive to both TNF-α, FasL and TRAIL (Supplementary Fig. 3A), we 
monitored the role of each DR in the cytotoxic effect of DCsup using 
soluble death ligand antagonists. MoDCs were activated with CL075 or 
LPS for 30 min and supernatants of DCs were collected after 2 and 8 or 
24 h, respectively. The actDC supernatant was pre-treated with TNF:Fc, 
Fas:Fc or TRAIL:Fc to neutralize the possible ligands in the supernatant. 
All these supernatants were cytotoxic to Jurkat cells and TNF:Fc alone 
inhibited this effect. Fas:Fc or TRAIL:Fc were unable to block cell death 
regardless of how long the supernatant was produced (Fig. 2). 
Supporting the observed TNF-dependent cytotoxicity, we detected 
significant TNF-α production by DCs after CL075 or LPS pre-activation 
(Supplementary Fig. 3B). These observations suggest that PRR 
activation-induced TNF-α production is responsible for short-term acti-
vated DC-mediated cytotoxicity. 
3.3. RIPK1 is required for DCsup-induced cell death 
It has been published that TNF receptor ligation induces both RIPK1- 
dependent and independent cell death (Wang et al., 2008). We previ-
ously reported that the supernatant of activated T cells induced RIPK1 
dependent Fas-mediated apoptosis (Koncz et al., 2012) and we were 
curious to know whether RIPK1 was also required for DCsup-induced 
cell death. Therefore, we compared the susceptibility of Jurkat cells 
and their RIPK1 deficient subclones to DCsup-induced cytotoxicity. 
Treatment with the supernatants of both CL075- and LPS-activated DCs 
resulted in more intensive cell death in wild-type cells than in their 
RIPK1-deficient counterparts (Fig. 3A). 
During RIPK1-dependent apoptosis, RIPK1 recruits procaspase-8 and 
FADD, thus forming a cell death-inducing platform, referred to as a 
“ripoptosome” (Tummers and Green, 2017). To analyse the interaction 
between RIPK1 and pro-caspase-8, RIPK1 was immunoprecipitated from 
Jurkat cells after DCsup-induced activation. We found that caspase-8 is 
associated with RIPK1 after treatment of cells with the supernatants of 
CL075- or LPS-activated DCs, but not in the presence of the supernatant 
of unstimulated moDC (Fig. 3B). The intensity of RIPK1/caspase-8 as-
sociation was similar in DCsup-treated and TNF plus SMAC mimetic- 
treated samples, the latter is a frequently used stimulus to activate 
RIPK1-dependent cell death (Wang et al., 2008). We confirmed these 
results by immunoprecipitating caspase-8 from Jurkat cells after DCsup- 
induced activation (Fig. 3C). RIPK1 phosphorylation is a widely 
accepted marker to characterize RIPK1-mediated cell death pathways 
(Geng et al., 2017). We detected increased phosphorylation of RIPK1 in 
Jurkat cells treated with either CL075 or LPS-activated DCsup but not 
after treatment with unstimulated DC supernatant (Fig. 3D). Altogether 
our results indicate that RIPK1-driven signaling contribute to DCsup- 
induced cell death. 
3.4. The supernatant of dendritic cells activates RIPK1-dependent 
apoptosis 
In addition to apoptosis, RIPK1 also mediates necroptosis when 
caspase-8 activity is blocked, and consequently it is unable to inhibit the 
necroptotic proteins (Geng et al., 2017). To determine whether DCsup 
stimulates RIPK1-mediated apoptosis or necroptosis, we treated the 
target cells with the DCsup in the presence of the pan caspase inhibitor 
(Z-VAD) and the necroptosis inhibitor (necrostatin-1). Pre-treatment of 
Jurkat cells with 10 μM Z-VAD inhibited DCsup-induced apoptosis 
(Fig. 4A). In addition, Z-VAD pre-treatment almost completely reduced 
cell death detected by PI-uptake (Fig. 4B). Necrostatin-1, however, did 
not have any effect on cell death (Fig. 4 A-B) nor was it additive to the Z- 
VAD-mediated inhibition. These results indicate that DCsup induces 
caspase-dependent apoptotic but not necroptotic cell death. 
3.5. Tolerogenic microenvironment reduces the cytotoxic capacity of DCs 
We hypothesized that DCs induce cell to allow the sampling of dead 
cell-derived antigens from the surrounding microenvironment. To check 
whether controlling the availability of intracellular antigens is a 
constitutive function of DCs or it is also regulated by the surrounding 
tissues, we modelled the effects of tolerogenic and also immunogenic 
conditions. For this, according to previously published protocols (Sauter 
et al., 2019; Carbonneil et al., 2004), DCs were pre-treated with dexa-
methasone to induce the differentiation of tolerogen DCs, or with type I 
IFNs to mimic intracellular infection. To confirm the differentiation of 
these cells, we examined the production of inflammatory and tolero-
genic cytokines in each differentiated DC population following LPS or 
CL075 activation. IFN-treated DCs produced significantly higher level of 
IL-6 than the tolerogen DCs, but dexamethasone-pre-treated DCs 
Fig. 2. moDC supernatant induces cell death in a TNF-dependent manner. DCs were stimulated on day 5 of the differentiation with Toll-like receptor ligands CL075 
(1 μg/ml, Sigma) and LPS (0.5 μg/ml, InvivoGen) for 30 min. After washing steps DCs were incubated in fresh serum-free RPMI 1640 medium (Sigma) for 2, 8 or 24 h 
and the supernatants of DCs were harvested. The supernatants of DCs were pre-treated with TNF:Fc, Fas:Fc or TRAIL:Fc for 1 h. SVT35 Jurkat cells were activated 
with TNF:Fc, Fas:Fc or TRAIL:Fc pre-treated supernatants for 24 h. Cell death was determined by measuring the subG1 peak. The figures show the average of at least 
three independent experiments. 
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secreted more IL-10 (Supplementary Fig. 4A-B). We checked the cyto-
toxic capacity of polarized DCs, by treating all these subpopulations with 
LPS or CL075 and examined the effect of their supernatants on Jurkat 
cells. The supernatant of dexamethasone-pre-treated DCs induced 
significantly less intense cell death than that of normal DCs, while cell 
death increased slightly, but not significantly after exposure of Jurkat 
cells to the supernatant of IFN-pre-treated DCs (Fig. 5A). 
To determine whether the immunomodulatory environment also 
affects the susceptibility of target cells to DC-induced cytotoxicity, we 
treated the Jurkat cells were with type I IFN or with tolerogenic cyto-
kines such as IL-10 and TGFβ. Regardless of pre-treatment of the target 
cells, the DC supernatant induced comparable cell death. However, IFN 
pre-treatment slightly, though not significantly, elevated cell death in-
tensity (Fig. 5B). We can conclude that the tolerogenic microenviron-
ment reduces the DC-induced cytotoxicity, and this effect is due to the 
reduced killing capacity of DCs rather than an acquired resistance of 
Fig. 3. RIPK1 is required for DCsup-induced cell death. (A) SVT35 Jurkat cells 
and their RIPK1-negative sub-clones were treated with the supernatants of 
unstimulated, CL075-(1 μg/ml) or LPS- (0.5 μg/ml) activated DCs for 24 h and 
cell death was determined by measuring the subG1 peak. The figure shows the 
average of five independent experiments. (B-C) SVT35 Jurkat cells were acti-
vated with the supernatants of unstimulated, CL075-(1 μg/ml), or LPS- (0.5 μg/ 
ml) activated DCs or with the combination of TNF-α (20 ng/ml) and SMAC 
mimetic (0.5 μM) (TNF + SM) for 1 h. Following immunoprecipitation with 
anti- RIPK1 (B) or anti-Caspase-8 (C), the recruited molecules were visualized 
by western blotting. (D) The phosphorylation of RIPK1 was detected from total 
cell lysates by western blotting following the activation with the supernatants 
of unstimulated, CL075-(1 μg/ml), or LPS-(0.5 μg/ml) activated DCs or with the 
combination of TNF-α (20 ng/ml) and SMAC mimetic (0.5 μM) (TNF + SM) for 
1 h. Representative images of three independent experiments are shown. 
Fig. 4. The supernatant of dendritic cells activates apoptosis. (A) SVT35 Jurkat 
cells were pre-treated with either 10 μM Z-VAD or 40 μM necrostatin-1 alone or 
in combination for 1 h and were treated with the supernatants of unstimulated, 
CL075-(1 μg/ml), or LPS-(0.5 μg/ml) activated DCs for 24 h. Cell death was 
determined by measuring the subG1 peaks or (B) by the uptake of PI. The 
figures show the average of five independent experiments. 
Fig. 5. Tolerogenic microenvironment reduces the cytotoxic capacity of DCs. 
(A) SVT35 Jurkat cells were treated with the supernatants of untreated, CL075- 
(1 μg/ml) or LPS-(0.5 μg/ml) activated, control DCs (moDC), IFN-pre-treated 
DCs (IFN DC), or dexamethasonepre- treated (dexa) DCs for 24 h. Cell death 
was determined by measuring the subG1 peak. (B) SVT35 Jurkat cells were pre- 
treated with 100 ng/ml IL-10 and/or 100 ng/ml TGFß or 0.6 million U/ml IFN- 
α for 1 h. Following pre-treatment, these ligands were washed out completely 
and SVT35 Jurkat cells were triggered with the supernatant of unstimulated, 
CL075-(1 μg/ml) or LPS- (0.5 μg/ml) activated DCs for 24 h. Cell death was 
determined by measuring the subG1 peaks. The figures show the average of 
three independent experiments. 
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Dying cells may also activate innate and adaptive immune response 
in addition to tolerogenic apoptosis. Accidental necrosis or regulated 
necrotic pathways result in the release of damaged molecules (DAMP) 
from dying cells and consequently induce inflammation. RIPK1- 
dependent processes (Galluzzi et al., 2018; Yatim et al., 2015; Hancz 
et al., 2018), which facilitate effective uptake and presentation of dead 
cell-derived antigens, induce immunogenic cell death and initiate the 
response of naive CD8+ T cells (Galluzzi, 2020). Consequently, various 
cell death inductions can be determinative in the regulation of immune 
response. 
DCs are known to have cytotoxic potential, but the immunological 
role of this process is highly questionable (Chan and Housseau, 2008; 
Chauvin and Josien, 2008). The limited number of DCs already pre-
cludes the role of DCs in the effective killing of tumors or virus-infected 
cells. In addition, DCs migrate from the site of infection shortly after 
activation. Therefore, DC-induced cytotoxicity may be more important 
for efficient cross-representation by facilitating the acquisition of anti-
gens, but is unlikely to function in the elimination of pathogens. 
Accordingly, 24 hours LPS preconditioned DCs lose their killer function 
while losing their phagocytic ability. To confirm this hypothesis, we 
examined RIPK1-mediated signaling in dying cells, which has been 
shown to be a specific mode of cell death that promotes efficient cross- 
representation (Yatim et al., 2015). Comparing RIPK1 positive and 
RIPK1 deficient Jurkat cell lines, we found that DC-induced killing is at 
least partially a RIPK1-dependent process. These results confirm that 
DCs induce immunogenic cell death to facilitate their access to intra-
cellular antigen fragments. It is important to note that PRR activation is 
required for inducing DCs’ cytotoxicity, so killing for sampling is not a 
continuous process. However, the external LPS signal, which is recog-
nized primarily by cell surface PRR receptors, was effective in activating 
the cytotoxic function of DCs, indicating that the DCs themselves do not 
need to be infected to initiate their killer function. 
If DC-induced cytotoxicity is not a constitutive surveillance mecha-
nism, then we can assume that the tissue environment is able to regulate 
this process. Pre-treatment of DCs with dexamethasone is a widely used 
method for modelling tolerogenic DCs (Im et al., 2014). We compared 
the cytotoxic capacity of dexamethasone- and type I IFN-treated DCs. We 
have shown that tolerogenic stimuli reduces the DCs’ killing capacity. 
Previous reports have shown that DCs can directly eliminate tumor cells 
and induce anti-tumor responses by taking up apoptotic tumor cells. Our 
results indicate that the immunosuppressive environment that charac-
terizes most of tumors (Galluzzi, 2020) can significantly block DCs’ 
cytotoxic activity. 
Immunomodulatory cytokines, type I IFNs are originally described as 
inducers of the antiviral response (Isaacs and Lindenmann, 1957). Sur-
prisingly, the presence of type I IFN did not significantly change DC- 
induced cytotoxicity. PRR-induced activation of DCs triggers the 
killing function of DCs even without the paracrine effect of interferon 
produced by infected cells. It is well known that type I IFN mediates 
potent immunostimulatory effects, but this depends more on increased 
MHC expression, efficient cross-presentation, or directed chemotaxis of 
dendritic cells (Schiavoni et al., 2013) than on the elevated cytotoxic 
function of DCs. However, IFN also causes the maturation of DCs, a 
process that can down-regulate and compensate for the increased killing 
potential (Chauvin and Josien, 2008). 
Mechanistically, DC-driven cytotoxicity was mediated by TNF 
secretion, but we could not detect the role of FasL or TRAIL in DCsup- 
induced killing. Depending on the gathered molecular complexes, TNF 
receptors can induce either apoptosis or necroptosis (Wang et al., 2008). 
Using specific inhibitors for apoptotic and necroptotic processes, we 
demonstrated that DCsup induces almost exclusively apoptosis. 
In summary, we have shown that DC-induced cytotoxicity is at least 
in part a RIPK1-dependent process, which confirms the hypothesis that 
the ambition of DC-mediated killing is to facilitate the cross- 
presentation of intracellular antigens to CD8+ T cells. The tolerogenic 
microenvironment downregulates the cytotoxic ability of DCs and 
thereby prevents the presentation of intracellular antigens. This toler-
ogen mechanism can play a role in reducing unwanted reactions to auto- 
antigens, but it can also inhibit the effective cross-presentation of tumor 
antigens. 
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